World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
44943
World Ranking
5984
National Ranking
3197

Steven P. Balk publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Steven P. Balk sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 373 publications — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Steven P. Balk D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Steven P. Balk sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Steven P. Balk is affiliated with Beth Israel Deaconess Medical Center in the United States and has a research focus predominantly in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans several subfields, including Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research, and Immunology.

The main topics of research covered by this scientist include:

  • Prostate Cancer Treatment and Research
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Lipids, and Metabolism
  • Ubiquitin and proteasome pathways
  • PARP inhibition in cancer therapy
  • Immunotherapy and Immune Responses
  • Epigenetics and DNA Methylation

Steven P. Balk has contributed to multiple publications across a variety of scientific journals and venues. Frequent publication venues include:

  • Cancer Research (12 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (11 publications)
  • The Prostate (9 publications)
  • Clinical Cancer Research (5 publications)
  • Nature Communications (4 publications)

Their frequent co-authors include Eva Corey, Joshua W. Russo, Peter S. Nelson, David J. Einstein, and Jill A. Macoska.

Recent papers authored or co-authored by Steven P. Balk highlight advances in prostate cancer research and related therapeutic resistance mechanisms:

  • "Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer," 2020, Cancer Cell
  • "EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer," 2021, Nature Cancer
  • "Transcriptional mediators of treatment resistance in lethal prostate cancer," 2021, Nature Medicine
  • "Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer," 2020, Nature Genetics
  • ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer," 2020, Cancer Research

Steven P. Balk has been recognized as a Member of the Association of American Physicians.

Best Publications

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

    Mary-Ellen Taplin;Glenn J. Bubley;Todd D. Shuster;Martha E. Frantz

  • Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer

    Michael Stanbrough;Glenn J. Bubley;Kenneth Ross;Todd R. Golub

  • Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain.

    Steven Porcelli;Courtland E. Yockey;Michael B. Brenner;Steven P. Balk

  • Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer

    Qianben Wang;Wei Li;Yong Zhang;Xin Yuan

  • Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes

    S. Brian Wilson;Sally C. Kent;Kurt T. Patton;Tihamer Orban

  • Biology of prostate-specific antigen.

    Steven P. Balk;Yoo Joung Ko;Glenn J. Bubley

  • EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent

    Kexin Xu;Zhenhua Jeremy Wu;Anna C. Groner;Housheng Hansen He

  • Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist

    Mary-Ellen Taplin;Glenn J. Bubley;Yoo-Joung Ko;Eric J. Small

  • Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants

    Elahe A. Mostaghel;Brett T. Marck;Stephen R. Plymate;Robert L. Vessella

  • Recognition of cluster of differentiation 1 antigens by human CD4 − CD8 >− cytolytic T lymphocyte

    Steven Porcelli;Steven Porcelli;Michael B. Brenner;Michael B. Brenner;Julia L. Greenstein;Cox Terhorst

  • Requirements for CD1d Recognition by Human Invariant Vα24+ CD4−CD8− T Cells

    Mark Exley;Jorge A. Garcia;Steven P. Balk;Steven Porcelli

  • Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

    Mary-Ellen Taplin;Steven P. Balk

  • Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and Metabolic Disorder through Regulatory Cytokine Production

    Lydia Lynch;Lydia Lynch;Michael Nowak;Bindu Varghese;Justice Clark

  • Erratum: Integrative Clinical Genomics of Advanced Prostate Cancer

    Dan Robinson;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer

    Sabina Signoretti;Rodolfo Montironi;Judith Manola;Annalisa Altimari

  • Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1

    Changmeng Cai;Housheng Hansen He;Sen Chen;Ilsa Coleman

  • Natural Ligand of Mouse CD1d1: Cellular Glycosylphosphatidylinositol

    Sebastian Joyce;Amina S. Woods;Jonathan W. Yewdell;Jack R. Bennink

  • Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

    Changmeng Cai;Sen Chen;Patrick Ng;Glenn J. Bubley

  • Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

    S M Tahir;O Cheng;A Shaulov;Y Koezuka

Frequent Co-Authors

Mark A. Exley
Mark A. Exley Brigham and Women's Hospital
Mary-Ellen Taplin
Mary-Ellen Taplin Harvard University
Richard S. Blumberg
Richard S. Blumberg Brigham and Women's Hospital
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Peter S. Nelson
Peter S. Nelson Fred Hutchinson Cancer Research Center
Massimo Loda
Massimo Loda Cornell University
Myles Brown
Myles Brown Harvard University
Housheng Hansen He
Housheng Hansen He University of Toronto
Steven A. Porcelli
Steven A. Porcelli Albert Einstein College of Medicine
Lawrence D. True
Lawrence D. True University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine does not always mean attending a traditional medical school. Today’s landscape includes many online degree options that support healthcare careers, often with more flexibility and lower costs.

For those interested in pharmacy, a 3 year online pharmd program offers an accelerated, remote path to becoming a pharmacist. This makes it easier to balance work and study while pursuing advanced credentials.

Beyond clinical care, him programs focus on electronic health records and data management—essential skills in modern healthcare administration.

For quick entry into the medical field, consider cheapest medical billing and coding online courses. These programs are ideal for acquiring industry-specific know-how and starting a healthcare career in months, not years.

Nursing career advancement is also possible through the cheapest online np programs, which lead to expanded clinical roles and higher salaries.

Best Scientists Citing Steven P. Balk

Trending Scientists

Recently Published Articles